30652-13-2

Basic information

• Product Name: 1-propyl-2-methyl-3-hydroxypyrid-4-one
• Synonyms: 1-propyl-2-methyl-3-hydroxypyrid-4-one;1-Propyl-2-methyl-3-hydroxypyridin-4(1H)-one;3-Hydroxy-2-methyl-1-propylpyridine-4(1H)-one;CP-22;3-Hydroxy-2-methyl-1-propyl-1H-pyridin-4-one
• CAS NO: 30652-13-2
• Molecular Formula: C9H13 N O2
• Molecular Weight: 167.21
• Mol File: 30652-13-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 266°C at 760 mmHg
• Flash Point: 114.7°C
• Appearance: /
• Density: 1.132g/cm³
• Vapor Pressure: 0.00122mmHg at 25°C
• Refractive Index: 1.538
• CAS DataBase Reference: 1-propyl-2-methyl-3-hydroxypyrid-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-propyl-2-methyl-3-hydroxypyrid-4-one(30652-13-2)
• EPA Substance Registry System: 1-propyl-2-methyl-3-hydroxypyrid-4-one(30652-13-2)

Safety Data

• Hazardous Substances Data: 30652-13-2(Hazardous Substances Data)

Usage

Explanation

Different sources of media describe the Explanation of 30652-13-2 differently. You can refer to the following data:
1. This is the chemical name of the compound, also known as deferiprone.
2. Deferiprone is classified as a chelating agent because it binds to metal ions, specifically excess iron in the body.
3. Deferiprone is used to treat iron overload by binding to excess iron and promoting its excretion, thus reducing the risk of organ damage.
4. Deferiprone is commonly prescribed for patients with thalassemia, a genetic blood disorder that often requires frequent blood transfusions, leading to iron overload.
5. Deferiprone is available in tablet form, making it easy for patients to take as prescribed.
6. While deferiprone is generally well-tolerated, some patients may experience mild side effects such as gastrointestinal upset.
7. Deferiprone plays a crucial role in managing iron overload and mitigating its potential complications in patients with certain medical conditions.

Classification

Chelating agent

Medical use

Treatment of iron overload

Target patient population

Patients with thalassemia

Form

Tablet

Side effects

Generally well-tolerated, mild gastrointestinal upset in some patients

Role

Managing iron overload and mitigating potential complications

InChI:InChI=1/C9H13NO2/c1-3-5-10-6-4-8(11)9(12)7(10)2/h4,6,12H,3,5H2,1-2H3

Upstream product

• 107-10-8 propylamine 
• 118-71-8 Maltol 
• 3420-59-5 isomaltol 
• 24404-57-7 glucose-6-phosphate sodium salt 
• 82756-28-3 3-(β-D-galactopyranosyloxy)-2-furanyl methyl ketone 
• 90037-24-4 3-Benzyloxy-2-methyl-1-(propyl)-pyridin-4(1H)-one 
• 138548-48-8 5,6-Dihydro-3,5-dihydroxy-1-n-propyl-4H-pyridone 
• 51807-73-9 1-propylammonium acetate 
• 130752-64-6 Acetic acid 5-acetoxy-1-methyl-2-oxo-3-((2R,3R,4S,5R,6R)-3,4,5-triacetoxy-6-acetoxymethyl-tetrahydro-pyran-2-yloxy)-cyclopent-3-enyl ester 
• 20675-63-2 6-O-benzyl-D-galactose 
• 24822-33-1 D-isomaltose 
• 61049-69-2 3-O-benzylmaltol 

Relevant articles and documents

Synthesis, antimicrobial evaluation and QSAR study of some 3-hydroxypyridine-4-one and 3-hydroxypyran-4-one derivatives

A series of Mannich bases of 2-alkyl-3-hydroxy-pyridine-4-ones, namely 2-alkyl-3-hydroxy-5-N-piperidylmethyl or N,N-dialkylaminomethyl pyridine-4-ones 9, 10 and 15-18, two derivatives of N-aryl-2-methyl-3-hydroxy-pyridine-4-ones 19, 20 and two N-alkyl derivatives of maltol, 21 and 22 were prepared. They were screened for their antibacterial and antifungal activities against a variety of microorganisms using micro plate Alamar Blue assay (MABA) method. Multiple linear regressions (MLR) analysis was performed for the synthesized compounds as well as a series of pyridinone and pyranone derivatives 23-43 which have been synthesized and evaluated for antimicrobial activity by other researchers previously. Studied compounds showed a better quantitative structure-activity relationship (QSAR) model for the antimicrobial activity against Candida albicans and Staphylococcus aureus in comparison with other tested microorganisms.

Synthesis and in vitro trypanocidal activity of some novel iron chelating agents

This report describes the syntheses and in vitro trypanocidal activity of a number of iron(III) chelators against epimastigotes of Trypanosoma cruzi. The compounds examined included a number of lipophilic N-alkyl derivatives of 2-ethyl- and 2-methyl-3-hydroxypyrid-4-ones, N,N'-bis(o-hydroxybenzyl)-(±)-trans-1,2-diaminocyclohexane, cyclotetrachromotropylene and four commercially available carboxy derivatives of pyridine, pyrazine, and pyarazole. Benznidazole, the drug clinically used in the treatment of Chagas' disease in humans, served as standard. All compounds were screened in vitro against Trypanosoma cruzi epimastigotes at 50 and 100 μg/ml for 72 h of exposure. At 100 μg/ml dosage, at least 4 compounds exhibited high epimastigote growth inhibition (65-69%) comparable to benznidazole (72%), whereas 9 compounds showed moderate to fair activity (53-64%) in the in vitro assay. At the lower concentration (50 μg/ml), the inhibitory activity of the best of these compounds was reduced significantly (39-48%) compared to the standard drug (59%). The activity of all the carboxylic acids remained in the lower range (4-25%). It is hypothesized that the enhanced activity of some of the compounds is due to their increased lipophilicity which enables them to successfully pass through the cellular membrane of Trypanosoma cruzi epimastigotes. The trypanocidal activities of the most effective compounds were significantly reduced when tested in the presence of added ferric ion.

5,6-Dihydro-3,5-dihydroxy-4H-pyridones - A new maillard products from 6-O-substituted hexoses and primary amines

From reaction mixtures of n-propylamine and 6-O-substituted hexoses 1 (glucose-6-phosphate, isomaltose, 6-O-benzylgalactose) a previously unknown Maillard product, the 5,6-dihydro-3,5-dihydroxy-1-n-propyl-4H-pyridone (7a) was isolated in yields up to 20%.